期刊
JOURNAL OF HEADACHE AND PAIN
卷 18, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s10194-017-0813-3
关键词
Migraine; Tension-type headache; Cluster headache; Neurostimulation; Monoclonal antibodies; Patient-centeredness; Equity of healthcare; Nocebo
资金
- Allergan
- Amgen
- Biogen
- Brain Research
- GammaCore
- Genesis Pharma
- Eli Lily
- Merck-Serono
- Novatis
- Roche
- Sanofi-Genzyme
- Teva-Specifar
- Biogen-Genesis
- Elpen
- Pharmathen
- UCB
- Bayer
- Pfeizer
- Novartis
- Allergan Hellas
- Brain Therapeutics (Greece)
Background: We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. Methods: Questionnaires from 514 outpatients naive to neurostimulation and monoclonal antibodies were collected. Results: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. Conclusion: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据